<DOC>
	<DOCNO>NCT00701987</DOCNO>
	<brief_summary>A phase I trial evaluate safety tolerability ALS-357 administer four week topical ointment , escalate dos , patient cutaneous metastatic melanoma evaluate effect escalate dos topically apply ALS-357 histological remission cutaneous metastatic melanoma induction apoptotic biomarkers .</brief_summary>
	<brief_title>Safety , Tolerability , Preliminary Efficacy Study ALS-357 Patients With Cutaneous Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Study Participants must 18 year old . Study Participants must 2 site cutaneous metastatic melanoma remove surgery . Study Participants may previously treat chemotherapy immunotherapy 4 week first dose study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Cutaneous Metastatic Melanoma</keyword>
</DOC>